State Street SPDR S&P Pharmaceuticals ETF
XPH
69 hedge funds and large institutions have $93.1M invested in State Street SPDR S&P Pharmaceuticals ETF in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 17 closing their positions.
5.21% less ownership
Funds ownership: 47.14% → 41.93% (-5.2%)
10% less funds holding
Funds holding: 77 → 69 (-8)
13% less capital invested
Capital invested by funds: $107M → $93.1M (-$13.6M)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
44% less call options, than puts
Call options by funds: $420K | Put options by funds: $756K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fullerton Fund Management
Singapore
|
+$2.14M |
| 2 |
JP Morgan Chase
New York
|
+$1.43M |
| 3 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$724K |
| 4 |
Jane Street
New York
|
+$537K |
| 5 |
Millennium Management
New York
|
+$318K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.04M |
| 2 |
CF
Centaurus Financial
Anaheim,
California
|
-$2.63M |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$1.93M |
| 4 |
FIM
FWL Investment Management
Dallas,
Texas
|
-$1.68M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.66M |
XPH Hedge Fund Activity: Q1 2022 in Review
69 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2022, worth a combined $93.1M — down 13% from $107M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of XPH and 11 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was Fullerton Fund Management, opening a new position worth an estimated $2.14M. The largest seller was Goldman Sachs, cutting an estimated $3.04M.
- 69 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2022, down from 77 in Q4 2021.
- Funds reported $93.1M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2022, down 13% quarter-over-quarter.
- 11 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2022 and 17 closed out, a net change of -6 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2022 was Fullerton Fund Management, an estimated $2.14M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2022 was Goldman Sachs, an estimated $3.04M sold.
Based on aggregated 13F filings for Q1 2022.